Tanya Gupta, MD, discusses the use of ado-trastuzumab emtansine for the treatment of patients with HER2-positive breast cancer.
Tanya Gupta, MD, medical oncologist in the Stanford University Department of Medicine, Division of Medical Oncology, discusses the use of ado-trastuzumab emtansine (T-DM1; Kadcyla) for the treatment of patients with HER2-positive breast cancer.
Ado-trastuzumab emtansine, which combines trastuzumab with a cytotoxic agent, was the first antibody-drug conjugate (ADC) to be approved in the HER2-positive space in 2013. This approval was largely supported by findings from the KATHERINE study (NCT01772472). The phase 3 clinical trial sought to compare adjuvant T-DM1 with trastuzumab in patients with HER2-positive early breast cancer who had residual invasive disease after receiving neoadjuvant therapy.
In the study, T-DM1 was shown to significantly improve outcomes for patients with HER2-positive early breast cancer and residual invasive disease after neoadjuvant therapy. T-DM1 significantly improved invasive disease-free survival, reducing the risk of recurrence or death by 50% compared with trastuzumab, setting a new standard of care for this patient population.
While T-DM1 remains a mainstay of treatment for patients with HER2-positive disease, Gupta explains that newer ADCs like fam-trastuzumab deruxtecan-nxki (Enhertu; T-DXd), and sacituzumab govitecan (Trodelvy) are advancing the field even further. Newer ADCs like these continue to improve outcomes for patients with difficult-to-treat breast cancers.
Transcription:
0:09 | T-DM1 is indicated for both adjuvant HER2-positive disease and metastatic HER2-positive disease. In the adjuvant setting, it is specifically indicated for patients who have been treated neoadjuvantly and then have residual disease at the time of surgery based on the results of the KATHERINE study [NCT01772472]. This study demonstrated that adjuvant T-DM1 is associated with an improved median overall survival and invasive disease-free survival as compared [with] adjuvant trastuzumab.
0:43 | Now, in the metastatic setting, T-DM1 has been shown to be more efficacious than capecitabine and lapatinib [Tykerb] as based on the EMILIA trial [NCT00829166]. And because of this, for some time, T-DM1 was our favored second-line therapy for metastatic HER2-positive disease. But as we will discuss, T-DXd is now the favored second-line therapy.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More
ctDNA Detection Tied to Tumor Burden, Recurrence in HR+ Early Breast Cancer
December 13th 2024A phase 2 trial showed ctDNA detection in HR-positive early breast cancer was linked to larger tumors, higher residual cancer burden, and increased recurrence after neoadjuvant endocrine therapy.
Read More